Gujarat Themis Biosyn Reports Q1 FY2026 Results, Announces Board Changes and New API Plant Aug 01, 2025
Gujarat Themis Biosyn Reports Q1 Results, Appoints New Director, and Commences API Plant Operations Aug 01, 2025
Gujarat Themis Biosyn Reports Q1 Results, Announces Board Changes and New API Plant Aug 01, 2025
More news about Gujarat Themis Biosyn
01Aug 25
Gujarat Themis Biosyn Reports Q1 Decline and Board Reshuffles
Gujarat Themis Biosyn Limited (GTBL) reported a 31.06% decrease in net profit to ₹91.00 crore and a 7.71% decline in revenue to ₹359.00 crore for Q1. The company appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director and announced the upcoming cessation of Mr. Siddharth Kusumgar's term. GTBL decided to focus on its core business of fermentation-based pharmaceutical intermediates and APIs, abandoning the proposed merger with Themis Medicare Limited. The company also began commercial production at its new API plant in Vapi, Gujarat.
20May 25
Gujarat Themis Biosyn Reports Decline in Q4 Financial Performance
Gujarat Themis Biosyn's Q4 results show a decline in key financial metrics. Revenue decreased by 10.1% to ₹377.4 crore, while net profit fell 25% to ₹120 crore compared to the previous year. EBITDA dropped 23.3% to ₹160.4 crore, with the EBITDA margin contracting to 42.5% from 49.82%. The company faces challenges across revenue, profitability, and operational efficiency.
06May 25
Gujarat Themis Biosyn Launches Commercial Production at New API Plant
Gujarat Themis Biosyn Ltd (GTBL) has commenced commercial production at its new Active Pharmaceutical Ingredient (API) plant in Gujarat. This strategic move aims to enhance the company's manufacturing capabilities and expand its market reach. The new facility is expected to strengthen GTBL's forward integration initiatives, potentially improving profit margins and supply chain control. The company is focusing on reinforcing its position in key export markets, particularly the United States and Europe. This expansion signifies GTBL's commitment to growth and innovation in the pharmaceutical sector, positioning it to meet increasing global demand for high-quality APIs.